In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER. Sanofi (SNY) confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- SNY Upcoming Earnings Report: What to Expect?
- Sanofi Advances with Cialis Trial and EU Approval for Sarclisa
- Insulin prices have dropped but some poor patients are paying more, NYT says
- Drugmakers to push Trump to pause price negotiations, Bloomberg reports
- Sanofi Advances Multiple Myeloma Treatment with Sarclisa Innovations